Security Snapshot

MIRATI THERAPEUTICS INC - COM (MRTX) Institutional Ownership

CUSIP: 60468T105

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2024

13F reference period

n/a

Institutions Reporting

Shares (Excl. Options)

n/a

Price

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / COM
Symbol
MRTX
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • MRTX - MIRATI THERAPEUTICS INC - COM is tracked under CUSIP 60468T105.
  • 13F reference-period holder data is not available.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder data for the Q2 2026 reference period is not available.
  • Available periods remain in the history table; they do not substitute for the headline period.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

60468T105

13F reference period

n/a

13F holders

13D/G owners

0

CIK / CUSIP context first

MRTX full holder history

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
42
Headline period
n/a
Rows shown
1-25 of 42
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2024 Q2 0 $0 -$26,433 0
2024 Q1 43 $2,525 -$4,464,062,363 $58.72 2
2023 Q4 79,275,905 $4,657,835,903 +$14,045,563 $58.75 214
2023 Q3 81,015,221 $3,529,100,894 +$678,498,915 $43.56 212
2023 Q2 65,867,654 $2,380,350,563 +$61,643,418 $36.13 205
2023 Q1 64,072,708 $2,379,835,109 -$56,796,001 $37.18 219
2022 Q4 65,482,242 $2,966,731,069 -$56,815,150 $45.31 231
2022 Q3 63,558,869 $4,438,430,260 +$56,071,596 $69.84 234
2022 Q2 62,636,989 $4,206,428,893 +$294,727,854 $67.13 221
2022 Q1 57,270,400 $4,709,749,015 -$96,675,294 $82.22 243
2021 Q4 56,810,456 $8,331,650,740 +$260,316,448 $146.69 248
2021 Q3 54,192,030 $9,586,786,560 +$202,014,736 $176.91 235
2021 Q2 53,049,085 $8,569,104,822 -$95,645,396 $161.53 241
2021 Q1 50,069,930 $8,578,534,607 +$129,172,057 $171.30 254
2020 Q4 49,366,833 $10,842,833,809 +$883,958,730 $219.64 279
2020 Q3 45,064,639 $7,483,008,247 +$24,152,868 $166.05 220
2020 Q2 48,512,828 $5,541,580,994 +$25,678,805 $114.17 197
2020 Q1 48,359,658 $3,716,493,515 +$432,192,189 $76.87 172
2019 Q4 42,695,607 $5,501,745,630 -$10,050,805 $128.86 188
2019 Q3 43,125,129 $3,360,052,841 -$42,534,401 $77.91 175
2019 Q2 43,518,939 $4,482,447,997 +$459,732,098 $103.00 170
2019 Q1 40,403,218 $2,961,551,852 +$372,725,379 $73.30 157
2018 Q4 35,494,849 $1,505,586,755 +$76,254,622 $42.42 111
2018 Q3 33,576,080 $1,581,467,120 +$87,519,242 $47.10 124
2018 Q2 31,664,389 $1,561,052,597 +$378,856,232 $49.30 107
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .